TORONTO, March 28, 2017 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its participation in the 2nd Annual Neuroscience Biopartnering and Investment Forum conference organized by Sachs Associates and held at the New York Academy of Sciences on March 27, 2017.
ProMIS Executive Chairman, Eugene Williams, presented an update and overview on the company's rapid progress and future outlook, and also contributed as a member of the expert panel entitled "Advances in Alzheimer's Disease".
"Following on from the Company's successful fund raise announced in February of this year, ProMIS will focus on progressing the development of its antibody program targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer's. Our lead development product, PMN310, is on track for IND submission at the end of 2018", stated Williams. "Furthermore, there is a substantial body of evidence from prior clinical trials in AD that targeting specifically the toxic, prion-like strains of Amyloid beta, while avoiding targeting of Amyloid beta monomer and plaque, will lead to best in class disease modifying therapy".
The Company overview presented at the meeting is available on the ProMIS Neurosciences website at:
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
SOURCE ProMIS Neurosciences Inc.
For further information: Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.firstname.lastname@example.org